Using Technology to Track Pain and Pain-related Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Luis F Buenaver, PhD
- Phone Number: 410-550-7000
- Email: lbuenav1@jhmi.edu
Study Contact Backup
- Name: Luis F Buenaver, Ph. D
- Phone Number: 410-550-7986
- Email: lbuenav1@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Recruiting
- Behavioral Medicine Research Lab
-
Contact:
- Katie Dunnock
- Phone Number: 410-550-6165
-
Principal Investigator:
- Luis Buenaver, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 21 years of age
- Pain duration > 3 months
- Average pain level of >3 out of 10 (0=no pain; 10=worst pain imaginable)
- English fluency
- Are not scheduled to undergo any medical procedures during the course of the study
- Have a physician-confirmed medical diagnosis associated with chronic pain
- Are willing to comply with the study protocol and give written informed consent. Patients taking non-narcotic analgesics must be on a stable dose one month prior to participation.
Exclusion Criteria:
- Delirium, dementia, or cognitive impairment (i.e., Mini Mental State Exam score <24)
- Unstable major psychiatric disorder or history of schizophrenia
- Beck Depression Inventory score >30 or report of suicidal ideation
- Active substance abuse;
- Refusal to provide access to relevant medical record information.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Navio App
The investigators propose to collect self-report and passively collected biological data and evaluate participants' relation to clinical and laboratory pain as well as patients' willingness to use and level of comfort with the mobile pain management digital platform and wearable biosensors.
Eligible participants will be consented, given two biosensors (i.e., Apple Watch Series 1 with KardiaBand; Spire), a sleep monitoring device (actigraph watch), and a mobile app enabled smartphone, then trained on how to use the app (and device if appropriate) and biosensors.
Participants will keep medications constant and not have any new pain treatment procedures over the course of the study period and 2 weeks prior to starting the study.
|
Participants will use the Navio Mobile App to track participants' pain and pain treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patterns of self-reported clinical Pain
Time Frame: Up to 2 weeks
|
Patients will complete twice-daily, electronic (i.e. via mobile app) numerical pain rating scales through Navio App.
|
Up to 2 weeks
|
|
Patterns of Pain Catastrophizing
Time Frame: Up to 2 weeks
|
Patients will complete twice-daily, electronic (i.e. via mobile app) pain catastrophizing questions through Navio App.
|
Up to 2 weeks
|
|
Patterns of Positive Mood
Time Frame: Up to 2 weeks
|
Patients will complete twice-daily, electronic (i.e. via mobile app) positive mood questions through Navio App.
|
Up to 2 weeks
|
|
Patterns of Negative Mood
Time Frame: Up to 2 weeks
|
Patients will complete twice-daily, electronic (i.e. via mobile app) negative mood questions through Navio App.
|
Up to 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Adherence as assessed by completion of questionnaire on the app
Time Frame: Up to 2 weeks
|
Daily and weekly patterns of electronic (i.e.
mobile app) questionnaire completion will be assessed to determine compliance with the use of the app.
|
Up to 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Luis F Buenaver, Ph. D, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00196831
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.